Despite the ongoing pandemic and difficult times for most of the industry, OSE has managed to progress its R&D activities, which most recently culminated in an out-licensing deal. All this helped the share price to triple since the beginning of 2020. OSE carried out a successful private placement of €18.6m in November 2020 followed by a substantial loan from the European Investment Bank in February 2021, which gives OSE access to up to €25m. The funding provides visibility to Q222, which could b ....
30 Apr 2021
OSE Immunotherapeutics - Transforming into R&D powerhouse
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
OSE Immunotherapeutics - Transforming into R&D powerhouse
- Published:
30 Apr 2021 -
Author:
Dr Jonas Peciulis -
Pages:
9
Despite the ongoing pandemic and difficult times for most of the industry, OSE has managed to progress its R&D activities, which most recently culminated in an out-licensing deal. All this helped the share price to triple since the beginning of 2020. OSE carried out a successful private placement of €18.6m in November 2020 followed by a substantial loan from the European Investment Bank in February 2021, which gives OSE access to up to €25m. The funding provides visibility to Q222, which could b ....